Skip to content
National Cancer Institute
U.S. National Institutes of Health
| www.cancer.gov
In English |
En español
Search
NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI
Clinical Trials Search Results
Quick Links
Director's Corner
Dictionary of Cancer Terms
NCI Drug Dictionary
Funding Opportunities
NCI Publications
Advisory Boards and Groups
Science Serving People
Español
Questions about cancer?
1-800-4-CANCER
LiveHelp® online chat
NCI Highlights
Virtual and Standard Colonoscopy Both Accurate
Denosumab May Help Prevent Bone Loss
Past Highlights
Results:
1 -10 of 26
Show
10
25
50
100
200
results per page
View Search Criteria
|
Help With Results
Sort By:
Phase of Trial
Title
Type of Trial
Status of Trial
Age Range
Sponsor of Trial
Protocol IDs
Version:
Health Professional
Patient
Format:
Short
------
Short
Medium
Long
Custom
1.
First Line Metastatic Colorectal Cancer Therapy in Combination With FOLFOX
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III, Phase II
Treatment
Active
18 and over
Pharmaceutical / Industry
D8480C00013
Eudract Number 2005-003440-66, NCT00384176
2.
Cediranib (AZD2171, RECENTIN™) in Addition to Chemotherapy in Patients With Untreated Metastatic Colorectal Cancer
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III
Treatment
Active
18 and over
Pharmaceutical / Industry
D8480C00051
EUDRACT No 2006-001194-14, HORIZON II, NCT00399035
Last Modified:
11/2/2007
 
First Published:
10/5/2007
3.
Phase III Randomized Study of Platinum-Based Chemotherapy (PBC) Comprising Carboplatin and Paclitaxel Versus Concurrent Cediranib and PBC Versus Concurrent and Maintenance Cediranib and PBC in Women With Platinum-Sensitive Relapsed Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Carcinoma
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III
Treatment
Active
18 and over
Other, Pharmaceutical / Industry
MRC-NCRI-ICON6
MRC-NCRI-ICON6, EUDRACT-2007-001346-41, EU-20765, ZENECA-MRC-NCRI-ICON6, NCT00544973
4.
A Phase I/II Study of AZD2171 in Japanese Metastatic Colorectal Cancer Patients in Combination With FOLFOX
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II, Phase I
Treatment
Active
18 and over
Pharmaceutical / Industry
D8480C00039
NCT00494221
Last Modified:
5/21/2008
 
First Published:
4/17/2008
5.
Phase I/II Study of Cediranib, Temozolomide, and Radiotherapy in Patients With Newly Diagnosed Glioblastoma
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II, Phase I
Biomarker/Laboratory analysis, Treatment
Active
18 and over
NCI
MGH-07-344
07-344, 8030, NCT00662506
Last Modified:
9/21/2007
 
First Published:
10/14/2005
6.
Phase II Study of AZD2171 in Patients With Recurrent or Stage IV Malignant Melanoma
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II
Treatment
Active
18 and over
NCI
PMH-PHL-038
7137, NCT00243061
Last Modified:
11/2/2007
 
First Published:
12/22/2005
7.
Phase II Study of AZD2171 in Patients With Early, Low-Volume Recurrent Ovarian Epithelial, Primary Peritoneal Serous, or Fallopian Tube Cancer
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II
Treatment
Active
18 and over
NCI
DFCI-05170
NCI-7102, 7102, NCT00275028
Last Modified:
5/13/2008
 
First Published:
3/24/2006
8.
Phase II Study of AZD2171 in Patients With Malignant Pleural, Peritoneal, or Tunica Vaginalis Mesothelioma That is Not Amenable to Curative Surgery
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II
Biomarker/Laboratory analysis, Treatment
Active
18 and over
NCI
UCCRC-14203B
NCI-7103, 7103, NCT00309946
Last Modified:
10/9/2008
 
First Published:
5/11/2006
9.
Phase II Randomized Study of Gemcitabine Hydrochloride and Carboplatin With Versus Without AZD2171 as First-Line Therapy in Patients With Stage IIIB or IV Non-Small Cell Lung Cancer
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II
Biomarker/Laboratory analysis, Treatment
Active
18 and over
NCI
NCCTG-N0528
N0528, NCT00326599
Last Modified:
5/8/2007
 
First Published:
5/11/2006
10.
Phase II Study AZD2171 in Patients With Neurofibromatosis Type 1 and Extensive Plexiform and/or Paraspinal Neurofibromas
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II
Treatment
Active
18 and over
NCI
MAYO-MC047F
7133, NCI-7133, NCT00326872
Select All on One Page
1
2
3
Next >
NCI Home
|
Images Version
|
Contact Us
|
Policies
|
Accessibility
|
Viewing Files
|
FOIA
|
Site Help
|
Site Map
A Service of the National Cancer Institute